Kansas City BioHub Secures $34 Million Federal Grant to Advance Biomanufacturing and Strengthen Domestic Drug Supply Chain
核心洞察
The U.S. Economic Development Administration (搜索) awarded approximately $34 million to the Kansas City BioSecure Manufacturing Tech Hub through the federal Tech Hubs program created by the CHIPS and Science Act.
KC BioHub (搜索) brings together businesses, universities, hospitals, manufacturers, and government agencies from Kansas and Missouri to focus on biomanufacturing of vaccines, biologic drugs, and advanced medicines.
The investment could help create thousands of jobs and generate an estimated $9.2 billion in economic activity over the next decade, according to KC BioHub (搜索).
The Kansas City BioSecure Manufacturing Tech Hub (KC BioHub (搜索)) has been awarded approximately $34 million in federal funding from the U.S. Economic Development Administration (搜索) (EDA), a move that positions the Kansas-Missouri region as a growing force in domestic biomanufacturing. The grant, announced through the federal Tech Hubs program established by the CHIPS and Science Act, is designed to bolster the nation's capacity to produce vaccines, biologic drugs, and other advanced medicines using living cells and biological processes.
KC BioHub (搜索) is a consortium that brings together businesses, universities, hospitals, manufacturers, and government agencies from both Kansas and Missouri. The partnership's core mission is to advance biomanufacturing capabilities while strengthening the domestic supply chain for critical medical products.
"This award is a vote of confidence in the strength of our regional assets, the depth of our partner relationships, and the promise of our shared vision for the future," said Melissa Roberts Chapman, President of KC BioHub (搜索). "Together, we have demonstrated that our region has the talent, infrastructure, partnerships, and innovation necessary to onshore the manufacturing of biologics. As a consortium, we have positioned the Kansas City region to lead in the global race to build the next great biotech ecosystem."
Economic and Workforce Impact
According to KC BioHub (搜索) projections, the investment could help create thousands of jobs and generate an estimated $9.2 billion in economic activity over the next decade. The grant will support projects aimed at improving drug development processes, expanding the region's biotechnology workforce, and reinforcing the domestic supply chain for medical products.
U.S. Secretary of Commerce Howard Lutnick emphasized the strategic importance of the award. "President Trump's leadership is positioning America at the center of advanced manufacturing," Lutnick said. "This award will position eastern Kansas and western Missouri as a global leader in advanced biomanufacturing for biologic medicines. It will modernize manufacturing processes, strengthen and retool domestic supply chains, and translate discoveries into scalable, resilient, and agile U.S. production of medications."
Bipartisan Support and National Security Implications
The funding announcement drew bipartisan praise from Kansas and Missouri elected officials. Republican U.S. Senator Jerry Moran highlighted his long-standing support for the CHIPS and Science Act and the Tech Hubs program.
"Today marks a significant milestone for the Greater Kansas City area and will help strengthen the future of bio and medical research and development throughout the region," Moran said. "I have long supported this program to give Kansas the opportunity to play a key role in supporting our national and economic security through increased research in biotechnology and other key technology areas."
Senator Roger Marshall, who had previously written to Commerce Secretary Howard Lutnick urging support for the project, framed the investment in terms of national security and pandemic preparedness. "The COVID-19 pandemic exposed the dangers of relying on foreign countries for our medicines and medical supply chains, and America cannot afford to make that mistake again," Marshall said. "The Kansas City region has the talent, research institutions, and manufacturing expertise to lead the next generation of biomanufacturing."
Democratic U.S. Representative Sharice Davids echoed the economic and strategic significance. "This is a huge win for Kansas City," Davids said. "Our region has everything it takes to lead the future of medical innovation, and this investment is proof that the rest of the country sees that, too. It will help create good-paying jobs, strengthen our regional economy, and reinforce America's supply chains and national security."
Regional Assets and Strategic Positioning
The Kansas City region's selection for this investment reflects its unique concentration of assets, including world-class research institutions, an advanced manufacturing base, the Animal Health Corridor, and the National Bio and Agro-Defense Facility. These resources, combined with a skilled workforce, position the region to play a pivotal role in onshoring biologic manufacturing and reducing dependence on foreign supply chains—a vulnerability underscored during the COVID-19 pandemic.
The grant represents one of the most significant federal investments in the region's biotechnology infrastructure and signals growing recognition of the Midwest's potential to contribute to the next generation of American biomanufacturing.